---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005555"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:42:56.436078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Aptose appoints EY as auditor, receives $1.5M advance from Hanmi for AML drug

## Summary
- Shareholders voted to appoint Ernst & Young as independent auditor at reconvened annual meeting.
- Received additional $1.5M advance from Hanmi under $8.5M loan facility, total drawn now $7.1M.
- Funds support continued clinical development of tuspetinib-based triplet therapy for AML.
- Aptose is a clinical-stage oncology company focused on front-line AML treatment.

## SEC filing metadata
- accession: 0001171843-25-005555
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325005555/0001171843-25-005555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325005555/f8k_082225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005555
- JSON: https://secwatch.observer/filing/0001171843-25-005555.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.